Chemical Biology Program
The Gabriela Chiosis Lab
The goal of my program is to investigate stressor maladaptation mechanisms such as they occur in several diseases. Our approach takes advantage of the way nature has evolved to control such stressors, and that is by a unique usage of the chaperome, referred here as the epichaperome. The epichaperome, which we discovered, is structurally, dynamically and functionally distinct from the housekeeping chaperome, and my lab has pioneered an approach to take advantage of such features. By using innovative methods, we develop small molecule chemical toolsets specifically targeted to the epichaperome; these act as “sensors” of the epichaperome, and in turn, of the chronic stressor-associated proteome-wide malfunctions. By the use of these unique toolsets we aim to understand, diagnose and treat cellular processes associated with chronic stressors. We address multiple mechanistic and biochemical questions less amenable to approaches that treat the chaperome as monolithic entity (i.e. the classical biochemical and genetic tools). We investigate in endogenous systems, both at the cellular and the organismal level, the inherent proteome changes and mechanisms that lead to disease, i.e. we can understand. By sensing disease states through the chemical toolsets, we go beyond investigation; we identify, measure and quantify, i.e. we can diagnose. By attacking the epichaperome specifically, we perturb the disease-causing proteome, and in turn revert or slow the disease phenotype, i.e. we can treat.
The epichaperome is an integrated chaperome network that facilitates tumour survival. Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G. Nature. 2016 Oct 5. doi: 10.1038/nature19807.
Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, Que NS, Taldone T, Finotti P, Stephani RA, Gewirth DT, Chiosis G. Nat Chem Biol. 2013 Sep 1. doi: 10.1038/nchembio.1335. [Epub ahead of print]
Identification of an allosteric pocket on human hsp70 reveals a mode of inhibition of this therapeutically important protein. Rodina A, Patel PD, Kang Y, Patel Y, Baaklini I, Wong MJ, Taldone T, Yan P, Yang C, Maharaj R, Gozman A, Patel MR, Patel HJ, Chirico W, Erdjument-Bromage H, Talele TT, Young JC, Chiosis G. Chem Biol. 2013 Dec 19;20(12):1469-80. doi: 10.1016/j.chembiol.2013.10.008. Epub 2013 Nov 14.
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross SS, Pillarsetty N, Ku T, Lewis JS, Larson SM, Levine R, Erdjument-Bromage H, Guzman ML, Nimer SD, Melnick A, Neckers L, Chiosis G. Nat Chem Biol. 2011 Sep 25;7(11):818-26. doi: 10.1038/nchembio.670.
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73. doi: 10.1073/pnas.0903392106. Epub 2009 May 5.
Gabriela Chiosis, PhD
- The Chiosis lab uses a unique chemical biology approach to understand, diagnose, and treat cellular processes associated with chronic molecular stress, with the ultimate goal of developing novel therapeutic options for use in the clinic.
- PhD, Columbia University
- [email protected]
- Email Address
- Office Phone
- +1 646 888 2238
- Lab Phone
AACR – Cancer Research and Prevention Career Development Award in Translational Lung Cancer Research, in Memory of Duffy Wall
Susan G. Komen Breast Cancer Translational Research Award
Frederick R. Adler Chair for Junior Faculty
Award for Drug Discovery Research for Frontotemporal Dementia
Top 5 percent cited author in Biology and Biochemistry 2010 (analysis by Thomson Reuters)
Translated from bench-to-bedside the Hsp90 inhibitor PU-H71 and the non-invasive companion diagnostic 124I-PU-H71 PET assay
Lab News & EventsA new strategy for Alzheimer’s disease treatment targets cell-wide protein malfunction
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Bioinformatics postdoctoral scientist
Postdoctoral researcher - Medicinal Chemistry and/or Chemical Biology
Postdoctoral researcher-translational research/biomedicine
Get in Touch
Lab Head Email
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Gabriela Chiosis discloses the following relationships and financial interests:
Samus Therapeutics LLC
Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].